Author Affiliations: Departments of Dermatology, Baylor College of Medicine, Houston, Texas (Dr Hsu), Mount Sinai School of Medicine of New York University (Dr Lebwohl), Columbia University (Dr Bagel), and New York University School of Medicine (Dr Strober), New York, New York, Oregon Health and Science University, Portland (Dr Blauvelt), University of Utah School of Medicine, Salt Lake City (Drs Callis Duffin and Krueger), University of California, Los Angeles (Dr Crowley), Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Feldman), Stanford University School of Medicine, Stanford, California (Dr Fiorentino), University of Pennsylvania, Philadelphia (Drs Van Voorhees and Wanat), Tufts University School of Medicine, Boston, Massachusetts (Drs Gottlieb and Michelon), State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo (Dr Kalb), Case Western Reserve University School of Medicine, Cleveland, Ohio (Dr Korman), Johns Hopkins at Green Spring, Lutherville, Maryland (Dr Morison), Henry Ford Hospital, West Bloomfield, Michigan (Dr Stein Gold), and University of Miami, Miami, Florida (Dr Weiss); Probity Medical Research, Waterloo, Ontario (Dr Papp); National Psoriasis Foundation, Portland, Oregon (Ms Jacobsen and Dr Bebo); Department of Pediatrics and Division of Dermatology, Department of Medicine, University of California, San Diego, School of Medicine (Dr Eichenfield), and Division of Rheumatology, Allergy, and Immunology, University of California, San Diego (Dr Kavanaugh); Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (Dr Gelfand); Department of Medicine, Allergy/Immunology and Rheumatology University of Rochester School of Medicine and Dentistry, Rochester, New York (Dr Ritchlin); and Division of Dermatology, Southern Illinois School of Medicine, Springfield (Dr Stone).
The Canadian Guidelines for the Management of Plaque Psoriasis were reviewed by the entire National Psoriasis Foundation Medical Board and updated to include newly approved agents such as ustekinumab and to reflect practice patterns in the United States, where the excimer laser is approved for psoriasis treatment. Management of psoriasis in special populations is discussed. In the updated guidelines, we include sections on children, pregnant patients or pregnant partners of patients, nursing mothers, the elderly, patients with hepatitis B or C virus infections, human immunodeficiency virus –infected patients, and patients with malignant neoplasms, as well as sections on tumor necrosis factor blockers, elective surgery, and vaccinations.
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus Guidelines for the Management of Plaque Psoriasis. Arch Dermatol. 2012;148(1):95-102. doi:10.1001/archdermatol.2011.1410